New drug for asthma, Singulair (montelukast)

    You'll see a new drug for asthma, Singulair (montelukast). Merck is launching it now in the U.S....later in Canada.

    Singulair is a leukotriene receptor antagonist...in the same class as Accolate (zafirlukast).

    They both block leukotrienes in the lungs that cause bronchoconstriction and inflammation. This can lead to fewer asthma attacks and decreased use of other asthma meds.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote